# Laboratory to Perform Assays of Coagulopathy Biomarkers for the National Cancer Institute’s COVID-19 in Cancer Patients Study (NCCAPS)

> **NIH NIH N02** · — · 2022 · $308,144

## Abstract

Lab will conduct coagulopathy assays for NCI to analyze as part of a correlative science objective in NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study, ClinicalTrials.gov Identifier: NCT04387656   https://clinicaltrials.gov/ct2/show/NCT04387656

## Key facts

- **NIH application ID:** 10582503
- **Project number:** 75N91021F00056-P00002-0-1
- **Recipient organization:** —
- **Principal Investigator:** EDWARD WONG
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $308,144
- **Award type:** —
- **Project period:** 2021-03-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10582503

## Citation

> US National Institutes of Health, RePORTER application 10582503, Laboratory to Perform Assays of Coagulopathy Biomarkers for the National Cancer Institute’s COVID-19 in Cancer Patients Study (NCCAPS) (75N91021F00056-P00002-0-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10582503. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*